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Abstract
Background: Dementia is a major and increasing health problem worldwide. This study aims to investigate
dementia treatment strategies among physicians specialised in complementary and alternative medicine (CAM) by
analysing prescribing patterns and comparing them to current treatment guidelines in Germany.
Methods: Twenty-two primary care physicians in Germany participated in this prospective, multicentre
observational study. Prescriptions and diagnoses were reported for each consecutive patient. Data were included if
patients had at least one diagnosis of dementia according to the 10th revision of the International Classification of
Diseases during the study period. Multiple logistic regression was used to determine factors associated with a
prescription of any anti-dementia drug including Ginkgo biloba.
Results: During the 5-year study period (2004-2008), 577 patients with dementia were included (median age: 81
years (IQR: 74-87); 69% female). Dementia was classified as unspecified dementia (57.2%), vascular dementia (25.1%),
dementia in Alzheimer’s disease (10.4%), and dementia in Parkinson’s disease (7.3%). The prevalence of anti-
dementia drugs was 25.6%. The phytopharmaceutical Ginkgo biloba was the most frequently prescribed anti-
dementia drug overall (67.6% of all) followed by cholinesterase inhibitors (17.6%). The adjusted odds ratio (AOR) for
receiving any anti-dementia drug was greater than 1 for neurologists (AOR = 2.34; CI: 1.59-3.47), the diagnosis of
Alzheimer’s disease (AOR = 3.28; CI: 1.96-5.50), neuroleptic therapy (AOR = 1.87; CI: 1.22-2.88), co-morbidities
hypertension (AOR = 2.03; CI: 1.41-2.90), and heart failure (AOR = 4.85; CI: 3.42-6.88). The chance for a prescription
of any anti-dementia drug decreased with the diagnosis of vascular dementia (AOR = 0.64; CI: 0.43-0.95) and
diabetes mellitus (AOR = 0.55; CI: 0.36-0.86). The prescription of Ginkgo biloba was associated with sex (female:
AOR = 0.41; CI: 0.19-0.89), patient age (AOR = 1.06; CI: 1.02-1.10), treatment by a neurologist (AOR = 0.09; CI: 0.03-
0.23), and the diagnosis of Alzheimer’s disease (AOR = 0.07; CI: 0.04-0.16).
Conclusions: This study provides a comprehensive analysis of everyday practice for treatment of dementia in
primary care in physicians with a focus on CAM. The prescribing frequency for anti-dementia drugs is equivalent to
those found in other German studies, while the administration of Ginkgo biloba is significantly higher.
Background
The management of dementia is a key challenge in mod-
ern health systems. The prevalence of dementia within
people aged 65 years or older is 6.8% [1,2]. It increases
with patient age and doubles every 5 years [3]. As the
proportion of people aged 65 years or older rises from
16.8% in 2010 to 23.5% in 2050, the number of dementia
cases will also increase from 1.21 million people today to
2.62 million people in 2050 in Germany alone [2]. It is
estimated that the number of sufferers from dementia
worldwide will increase from 35.6 million today to 65.7
million by 2030 and 115.4 million by 2050 [3]. The raise
in dementia patients is directly correlated with increasing
costs in the health care systems. While 7.1 million euros
were expended in Germany for treatment and care of
dementia in 2002, the costs increased to 7.8 million euros
in 2004, 8.6 million euros in 2006, and finally 9.4 million
euros in 2008 [4].
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most common types of age-related dementia. Alzheimer’s
disease accounts for more than 65% of dementia in the
elderly [1]. At present no curative treatment is available.
Interventions focus on slowing the course of the disease.
Compared with placebo, pharmacological treatment with
cholinesterase inhibitors and memantine has shown
improvements in outcomes such as cognition and global
functioning in Alzheimer’s disease [5,6]. However,
the clinical relevance of these treatment effects seems
marginal [7,8].
Some studies have indicated that complementary and
alternative medicine (CAM) from the areas of phytother-
apy, traditional Chinese medicine, or homoeopathy has
potential in the treatment of dementia [9-11]. In particu-
lar the phytopharmaceutical Ginkgo biloba is traditionally
used quite frequently [12,13]. In Germany, in contrast to
some other countries, Ginkgo biloba is available as pre-
scription drug for the therapy of mild to moderate
dementia. Although there is acceptable physiological
compatibility and sufficiently proven safety, there is still
an unclear picture of evidence [14,15]. According to the
meta-analysis of Weinmann et al. the change of scores
for cognition were in favour of Ginkgo biloba compared
to placebo, but they did not show a statistically signifi-
cant difference from placebo for activities in daily living
[16]. The German Institute for Quality and Efficiency in
Health Care (IQWIG) found only a small benefit for the
240 mg preparation and criticised the heterogeneity of
the study results [17]. In fact, Ginkgo biloba is not yet
included in evidence-based dementia guidelines pub-
lished in Germany.
The development, dissemination, and implementation of
these dementia guidelines are a key strategy for improving
the care of persons with dementia. In Germany one guide-
line from the German Society of General Physicians
(DEGAM) with a focus on family medicine was published
in 2008 while another one from the German Society of
Neurology and German Society of Gerontopsychiatry
(DGN and DGPPN) mainly for specialists was finalised in
2009 [18,19]. Unfortunately both guidelines reveal differ-
ent recommendations for the treatment of dementia,
which might be due to the abovementioned inconsistent
appraisal of clinical relevance from study results. The
DEGAM guideline is much more cautious in the recom-
mendation of cholinesterase inhibitors than the guideline
of the DGN/DGPPN, and while memantine is recom-
mended for Alzheimer’s disease in the guideline of the
DGN/DGPPN, the DEGAM only recommends it as an
individual approach for therapy [20].
In therapy for vascular dementia, recommended thera-
pies focus on the treatment of cardio-vascular risk fac-
tors, e.g. the prevention of prospective strokes. The
treatment of vascular dementia with anti-dementia drugs,
until now, did not produce a reliable portfolio of evidence
and thus the DEGAM does not give any recommenda-
tions where the DGN/DGPPN allows for a selective ther-
apeutic attempt in single cases. However, with respect to
the high amount of elderly patients, guidelines mainly
discuss the problems occurring with age-related co-mor-
bidity and poly-pharmacy.
Apart from two concurrent German guidelines, an addi-
tional barrier to guideline adherence is the difficulty faced
by physicians in reconciling patient preferences with
guideline recommendations [21]. According to studies in a
variety of primary care settings, patient expectations and
preferences can influence the health care provided to
them [22-24]. This issue may be particularly salient in the
setting of CAM, as patients seeking treatment from physi-
cians specialised in this field are likely to expect to receive
some form of alternative therapy. Furthermore, one should
not underestimate the impact of the physician’sc o n v i c t i o n
on the prescription practice. In a survey of German GPs,
ginkgo preparations for dementia were voted to be equally
as effective as cholinesterase inhibitors and memantine
[25].
The present study thus aims (a) to analyse prescribing
patterns among primary care physicians specialised in
CAM, b) to investigate conformity and variations in pre-
scriptions according to the German dementia guidelines
(DEGAM and DGN/DGNPP), c) to identify different
treatment strategies in GPs and neurologists and d) pro-
vide information of co-morbidities of patients with
dementia visiting primary health care physicians specia-
lised in CAM.
Methods
In total, 22 primary care physicians in Germany partici-
pated in this prospective, multicentre observational study.
All of them were members of the EvaMed Network, which
aims to evaluate CAM remedies in usual care with regard
to prescribing patterns, efficacy, and safety [26-28]. Physi-
cians were recruited through the German National Asso-
ciation of Anthroposophic Physicians (Gesellschaft
Anthroposophischer Ärzte in Deutschland; GAÄD). A total
of 362 physicians were contacted and informed about the
EvaMed Network by standard mail and, in the event of
non-response, 4 weeks later by telephone. For a physician
to be eligible to participate in the study, his or her medical
practice had to meet a number of technical requirements,
including the presence of a special computerised patient
documentation system (DocExpert, DocConcept, Tur-
boMed, Duria, PDE-Top, Medistar), a local area network
(LAN) connection, and Microsoft Windows and Internet
Explorer (i.e. as client software). A total of 38 physicians
(10.5%) fulfilled the technical requirements, gave informed
consent, and agreed to participate in the EvaMed Net-
work. Of these physicians, 16 specialised in paediatrics,
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study. Each of the remaining 22 physicians had practised
for at least 5 years in addition to completing training in
anthroposophic medicine.
The present study is based on secondary data provided
by physicians for health insurance accounting. As such,
the recommendations for good practice in secondary
data analysis (e.g. anonymisation of data on prescriptions
and diagnoses) developed by the German Working
Group on the Collection and Use of Secondary Data [29]
were applied in full.
Data were included if patients had at least one diagno-
sis of dementia according to the 10th revision of the
International Classification of Diseases (ICD10: F00-F03)
during the 5-year study period (01.01.2004-01.01.2009).
Data were excluded if the diagnosis dementia was only a
suspected diagnosis and not confirmed during the study
p e r i o da n di fac r o s s - v a l i d a t i o no ft h eI C D 1 0c o d ea n d
text of diagnosis indicated an incorrect coding. Figure 1
shows the flow chart of the inclusion process.
During the study, physicians continued to follow their
routine documentation procedures, recording diagnoses
and all prescriptions for each consecutive patient using
their existing, computerised patient documentation sys-
tem. These data were exported to the QuaDoSta post-
greSQL database hosted in each practice [30]. Physicians
used a browser-based interface to match individual diag-
noses with the corresponding drugs or remedies that had
been prescribed. Prescribed drugs were documented
using the German National Drug Code. Diagnoses were
coded according to the 10th revision of the International
Classification of Diseases (ICD-10).
Dementia was classified as ‘Dementia in Alzheimer’s dis-
ease’, ‘Vascular dementia’, ‘Dementia in Parkinson’sd i s -
ease’,a n d‘Unspecified dementia’. Co-morbidities were
classified as hypertension, depression, heart failure, chronic
ischemic heart disease, cardiac arrhythmias, diabetes melli-
tus, dyslipidemia, atherosclerosis, other cerebrovascular
diseases, pressure ulcer, stroke, cerebral infarction, arthro-
pathies, and dorsopathies. Multi-morbidity was considered
if a patient had at least 2 co-morbidities.
Study investigators identified all drugs and remedies pre-
scribed for dementia. Each substance was classified using
the Anatomical Therapeutic Chemical Index (ATC) and
anti-dementia drugs were clustered into cholinesterase
inhibitors (i.e. donepezil, rivastigmine, galantamine), mem-
antine, Ginkgo biloba, and older anti-dementia drugs (e.g.
piracetam, nimodipine, and selegiline). Other medication
was classified as antidepressants, anitpsychotics, benzodia-
zepine, anti-Parkinson drugs, antiepileptics, and sedatives.
Statistical analysis was performed with SPSS 18.0 for
Windows. Descriptive analysis was used to determine
prescription rates. Means and standard deviations (SD)
were calculated for continuous, normal data. In cases
where data were not normally distributed, medians and
interquartile ranges (IQR) were reported. Subgroup ana-
lyses of prescribing rates were performed for patient age
(under 60 years, 60-69 years, 70-79 years, 80-89 years,
90-99 years, 100 years and older), gender, and co-mor-
bidities. The two-tailed Chi square test was used to ana-
lyse differences in prescription rates. A P value of less
than 0.05 was regarded as indicating a statistically signifi-
cant difference.
Adjusted odds ratios (AOR) and 95% confidence inter-
vals (CI) were calculated using multiple logistic regressions
to determine factors associated with a) a prescription of
any anti-dementia drug and b) a prescription of Ginkgo
biloba versus cholinesterase inhibitors and/or memantine.
Age, sex, physician specialization (neurologist vs. GP), year
of prescription, type of consultation (first vs. follow up),
type of dementia, multi-morbidity, co-morbidities, neuro-
leptic, and antidepressant therapy were included as inde-
pendent variables. Patient age was introduced in the
model as a continuous variable. For the “best-fitting” logis-
tic regression model, we employed the stepwise Akaike
Information Criterion (AIC).
Results
Physicians
Of the 22 physicians, 17 were GPs (77%) and 5 were
specialist GPs (23%). The participating physicians did
not differ significantly from the overall population of
physicians certified in anthroposophy in Germany (n =
362) in terms of age (mean = 49.4; SD = 6.3 years vs.
mean = 47.5; SD = 6.1 years; P = 0.709) or gender
(60.0% vs. 62.2% men; P = 0.917), and were only slightly
younger and consisted of a similar percentage of women
compared to all office-based physicians in Germany
(mean 52.0 years; 61.2% men) [31].
Figure 1 Flow chart of the inclusion process.
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During the 5-year study period, a total of 577 patients
with dementia were included. The inclusion process is
shown in Figure 1. 374 patients (64.8% of all patients)
were treated by a GP and the remaining 203 patients
were treated by a neurologist. 69.2% of the patients were
female. The median age of the patients was 81 years
(IQR: 74, 87). Altogether, 4.9% of the patients were
under 60 years (n = 28), 10.1% were 60-69 years (n =
58), 27.2% were 70-79 years (n = 157), 41.4% were 80-
89 years (n = 239), 16.1% were 90-99 years (n = 93),
and 0.3% were 100 years or older (n = 2). Dementia was
classified as unspecified dementia (57.2%), vascular
dementia (25.1%), dementia in Alzheimer’s disease
(10.4%), and dementia in Parkinson’s disease (7.3%).
Table 1 shows the sample of patients according to age,
sex, and type of dementia.
In total, 76.4% of all patients (n = 441) had two or more
co-morbidities and were therefore classified as multi-mor-
bid. The most frequent co-morbidities were hypertensive
diseases (43.5% of all patients), other forms of heart dis-
ease (38.8%), dorsopathies (30.3%), arthropathies (29.8%),
mood [affective] disorders (27.7%), and ischemic heart dis-
eases (23.1%). Table 2 provides a detailed overview of the
most frequent co-morbidities of the participating patients
according to type of dementia.
Anti-dementia drug therapy
In total, 25.6% of all patients (n = 148) were prescribed
anti-dementia drugs (i.e. cholinesterase inhibitors, meman-
tine, or Ginkgo biloba). Table 3 gives a detailed overview of
the included patients according to anti-dementia drugs
and type of dementia. Most of the patients received Ginkgo
biloba (n = 99). 11.3% of all patients (n = 65) received an
anti-dementia drug therapy with cholinesterase inhibitors
or memantine. Cholinesterase inhibitors were prescribed
for 40 patients. Donepezil was the most frequently pre-
scribed cholinesterase inhibitor (n = 29), followed by
galantamine (n = 10) and rivastigmine (n = 8). In total,
32 patients were prescribed memantine. Thirty patients
were prescribed 2 or 3 different anti-dementia drugs,
mostly in combination with Ginkgo biloba (memantine
and Ginkgo biloba n = 10; cholinesterase inhibitors and
Ginkgo biloba n = 9; cholinesterase inhibitors and meman-
tine n = 8, cholinesterase inhibitors, memantine and
Ginkgo biloba n = 4). Only 6 patients received older anti-
dementia drugs like piracetam, nimodipine, and selegiline.
56.7% of patients with dementia with Alzheimer’sd i s -
ease received anti-dementia drugs, whereas less than 25%
of patients with other dementia types were prescribed
anti-dementia drugs (Table 3). Donepezil and memantine
were prescribed mostly for patients with dementia with
Alzheimer’s disease. The phytotherapeutical Ginkgo
biloba was prescribed for patients with dementia with
Alzheimer’s disease, vascular dementia, and unspecified
dementia in equal shares (16% - 20%). Patients with vas-
cular dementia were prescribed Ginkgo biloba (15.9%
Ginkgo biloba vs. 2.0% of any other anti-dementia drug)
nearly exclusively.
In total, 448 prescriptions of anti-dementia drugs for the
148 patients who received at least one of these drugs were
reported. The phytopharmaceutical Ginkgo biloba was the
most frequently prescribed anti-dementia drug overall
(67.6% of all anti-dementia drugs).
Prescriptions for dementia-related co-morbidities
The most frequent medication prescribed to patients for
dementia-relevant co-morbidities were antidepressants
(20% of all patients), antipsychotics (15%; thereof risperi-
done 7%, butyrophenone 7%), and benzodiazepine (10%).
Table 4 provides a detailed overview of these medications
according to type of dementia. In total, 18 patients
received the antidepressant CAM remedy Hypericum per-
foratum (14.6% of all patients with antidepressants). The
antipsychotic risperidone was prescribed for 7 patients
with dementia with Alzheimer’s disease, 7 patients with
vascular dementia, 2 patients with dementia with Parkin-
sons’s disease, and 24 patients with unspecified dementia.
Of the 40 patients being prescribed cholinesterase inhibi-
tors, only one received additional anticholinergic agents
during the study period.
There were significant differences in the proportion of
patients treated with an antidepressant (GP: 17.6%; neurol-
ogist: 28.1%; P = 0.003) and benzodiazepine (GP: 11.4%;
Table 1 Patients according to age, sex, and type of dementia
Dementia Patients Age [years] Sex [%]
Male Female
N Median (IQR) % %
Dementia in Alzheimer’s disease 60 79 (74.0; 85.0) 35.0 65.0
Vascular dementia 145 77 (69.5; 83.5) 33.1 66.9
Dementia in Parkinson’s disease 42 79 (74.5; 84.3) 38.1 61.9
Unspecified dementia 330 83 (76.5; 88.0) 28.1 71.8
Total 577 81 (74.0, 87.0) 30.8 69.2
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Page 5 of 11neurologist: 6.4%; P = 0.039) according to physician’s spe-
cialisation. No difference was found for the treatment with
antipsychotics (GP: 15.8%; neurologist: 14.3%; P = 0.635).
Factors related to any anti-dementia drug therapy
Table 5 shows the adjusted odds ratio (AOR) for factors
associated with the prescription of any anti-dementia
drug. The AOR for receiving any anti-dementia drug
was greater than 1 for the neurologists (AOR = 2.34; CI:
1.59-3.47), the diagnosis of Alzheimer’s disease (AOR =
3.28; CI: 1.96-5.50), hypertension (AOR = 2.03; CI: 1.41-
2.90), heart failure (AOR = 4.85; CI: 3.42-6.88), and neu-
roleptic therapy (AOR = 1.87; CI: 1.22-2.88). The odds
for a prescription of any anti-dementia drug decreased
with the diagnosis of vascular dementia (AOR = 0.64;
CI: 0.43-0.95) and diabetes mellitus (AOR = 0.55; CI:
0.36-0.86). Patient age, sex, consultation type (first vs.
follow up), multi-morbidity, and the year of prescription
had no influence.
Factors related to the prescription of Ginkgo biloba
The prescription of Ginkgo biloba was associated with
sex, patient age, physician’s specialisation, and the type
of dementia (Table 5). Older patients (AOR = 1.06; CI:
1.02-1.10) were more likely to receive Ginkgo biloba.
Female sex (AOR = 0.41; CI: 0.19-0.89), treatment by a
neurologist (AOR = 0.09; CI: 0.03-0.23), and the diagno-
sis of Alzheimer’s disease (AOR = 0.07; CI: 0.04-0.16)
rapidly reduced the odds of being prescribed Ginkgo
biloba,w h e r e a sc o - m o r b i d i t y ,c o-medication, consulta-
tion type, and the year of prescription had no influence.
Discussion
In this paper we present the results of a secondary data
analysis of electronic health record data from the
EvaMed Network, a German network of CAM-oriented
physicians. Overall, 25.6% of the patients with dementia
were prescribed anti-dementia drugs.
The prescription of any anti-dementia drug was posi-
tively associated with physicians specialising in neurology,
the diagnosis of Alzheimer’s disease, neuroleptic therapy,
co-morbidities hypertension, and heart failure. The odds
for a prescription of any anti-dementia drug decreased
with the diagnosis of vascular dementia and diabetes
mellitus.
In coherence with their orientation, the phytopharma-
ceutical Ginkgo biloba was the most frequently prescribed
anti-dementia drug overall (67.6% of all anti-dementia
Table 4 Sample of patients with dementia subdivided according to medication prescribed for dementia relevant co-
morbidities
Dementia Patients Medication
1
Antidepressants Antipsychotics Benzodiazepine Anti-Parkinson drugs Antiepileptics Sedatives
N [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)]
Dementia in Alzheimer’s
disease
60 20 (33.3) 22 (36.7) 9 (15.0) 7 (11.7) 7 (11.7) 7 (11.7)
Vascular dementia 145 15 (10.3) 12 (8.3) 13 (9.0) 4 (2.8) 4 (2.8) 8 (5.5)
Dementia in Parkinson’s
disease
42 13 (31.0) 11 (26.2) 3 (7.1) 28 (66.7) 28 (66.7) 3 (7.1)
Unspecified dementia 330 75 (22.7) 43 (13.0) 32 (9.7) 6 (1.8) 6 (1.8) 27 (8.2)
Total 577 123 (20.2) 88 (15.3) 57 (9.9) 45 (7.8) 45 (7.8) 45 (7.8)
1 Double entries possible
Table 3 Sample of patients with dementia subdivided according to anti-dementia drugs
Dementia Patients Anti-dementia drugs
1
Total Cholinesterase inhibitors Memantine Ginkgo
biloba
Donepezil Rivastigmine Galantamine
N [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)]
Dementia in Alzheimer’s disease 60 34 (56.7) 13 (21.7) 3 (5.0) 7 (11.7) 15 (25.0) 12 (20.0)
Vascular dementia 145 26 (17.9) 1 (0.7) - 1 (0.7) 1 (0.7) 23 (15.9)
Dementia in Parkinson’s disease 42 8 (19.0) 1 (2.4) 1 (2.4) 1 (2.4) 2 (4.8) 5 (11.9)
Unspecified dementia 330 80 (24.2) 14 (4.2) 4 (1.2) 1 (0.3) 14 (4.2) 59 (17.9)
Total 577 148 (25.6) 29 (5.0) 8 (1.4) 10 (1.7) 32 (5.5) 99 (17.2)
1 Double entries possible.
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Page 6 of 11drugs) even though it has not been recommended in
German dementia guidelines, while conventional anti-
dementia drugs, such as cholinesterase inhibitors and
memantine, ranged far behind. The prescription of Ginkgo
biloba was positively associated with patient age, whereas
the chance for the prescription of Ginkgo biloba was smal-
ler than 1 for women, treatment by a neurologist, and the
diagnosis of Alzheimer’s disease.
Study population
The median age of our study population was 81 years.
Compared to the recently published study of Olsson et
al. [32] conducted in nursing homes and special care
units, our patient population was slightly younger due
to the outpatient-character of this study but comparable
with data from German health insurance provided by
Koller et al. [33]. 69% of our patients were female,
which is similar to the proportion of women in demen-
tia patients in Germany (70% female) [34]. Considering
the high age of our population the frequent number of
co-morbidities is not surprising. Hypertension, conges-
tive heart failure, and ischemic heart diseases are parti-
cularly common in this age and are well known as
primers for vascular dementia and thus their occurrence
is an indicator for dementia in our population (see
Table 2).
Anti-dementia drug therapy
In our study almost 26% of patients received anti-demen-
tia drug therapy. According to the current ATC classifica-
tion, Ginkgo biloba is listed in the group of anti-dementia
drugs together with cholinesterase inhibitors and meman-
tine. Thus we counted Ginkgo biloba as an anti-dementia
drug although the literature is not consistent in this case.
This has to be taken into consideration when comparing
our results with other studies.
According to Formiga et al., 80.6% of the patients in a
Spanish population received cholinesterase inhibitors or/
and memantine for Alzheimer’s disease [35]. In an Italian
survey from 2007, Frisoni found a prescription rate of cho-
linesterase inhibitors in 90% of patients with Alzheimer’s
disease and 35-45% with vascular dementia. Other drugs,
such as Ginkgo biloba, were prescribed less frequently,
except for vascular dementia (20%) [36]. For Germany,
Stoppe et al. found that only 24% of patients with Alzhei-
mer’s disease were prescribed cholinesterase inhibitors in
2004 [37], which is comparable to our study.
Although both the results of our study and those of
Stoppe et al. [37] might be surprising at first, it has to be
taken into account that especially the DEGAM guideline
recommends a cautious and responsible handling of anti-
dementia drugs in dementia patients and thus the results
are in line with both the guidelines and the experience of
Table 5 Factors associated with any anti-dementia drug and Ginkgo biloba
Factor Adjusted OR (95% CI)
Any anti-dementia drug Ginkgo biloba
Sex
Male 1 1
Female 1.040 (0.748-1.448) 0.406* (0.186-0.887)
Age [years] 0.988 (0.972-1.005) 1.058* (1.018-1.100)
Physician specialisation
GP 1 1
Neurology 2.296* (1.557-3.384) 0.089* (0.034-0.232)
Type of dementia
Unspecified dementia 1 1
Dementia in Alzheimer’s disease 3.279* (1.959-5.496) 0.074* (0.035-0.156)
Vascular dementia 0.641* (0.433-0.948) 2.344 (0.701-7.837)
Dementia in Parkinson’s disease 0.856 (0.491-1.493) 1.003 (0.315-3.196)
Multi-morbidity
No 1 1
Yes 0.777 (0.497-1.214) 0.779 (0.403-1.504)
Hypertension 2.025* (1.413-2.901) 0.760 (0.334-1.732)
Heart failure 4.850* (3.419-6.880) 1.570 (0.684-3.603)
Chronic ischemic heart disease 0.822 (0.544-1.243) 0.751 (0.305-1.854)
Diabetes mellitus 0.553* (0.358-0.855) 2.549 (0.729-8.912)
Neuroleptic therapy 1.871* (1.217-2.876) 0.849 (0.393-1.833)
Antidepressant therapy 0.961 (0.649-1.422) 1.410 (0.655-3.038)
* AOR significantly different from 1.
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one of 42 patients was mainly treated with rivastigmine
which is recommended in the neurological guideline [19].
In 2006, a total of 50% of all prescribed anti-dementia
drugs in Germany were cholinesterase inhibitors and
memantine [13]. The most often prescribed anti-demen-
tia drug in Germany was the cholinesterase inhibitor
donepezil with 37% [38], which with a rate of 45% also
plays a predominate role in our study. Traditional anti-
dementia drugs like ergot alkaloids and piracetam,
which are not recommended in the treatment guide-
lines, have declined in their prescribing rates over in
recent years and, with only 6 patients, also play a minor
role in our setting.
In our study only 8 out of 148 patients (5.4%) were pre-
scribed both cholinesterase inhibitors and memantines
during the study period. This is comparable to Hoffmann
et al. who found only one anti-dementia drug in over
90% of his patients and Truter who only reported 5.3% of
patients that were prescribed more than one active ingre-
dient for Alzheimer’s disease during one year (mostly
donepezil or galantamine, and memantine) [38,39],
whereas Formiga found combined therapy of choline-
sterase inhibitors in 15.5% of patients [35]. While the
DEGAM guideline disapproves combination therapies
due to their low level of evidence, the DGN/DGPPN
guideline refers to 2 RCTs and claims that an add-on
therapy might be considered [18,19]. However, it has to
be noted that in our study concomitant treatment with
two drugs may also be a result of the course of therapy
and might not reflect a factual combination therapy.
Factors related to any anti-dementia drug therapy
According to Formiga, lower Barthel Index scores predict
fewer prescriptions of pharmcological therapy in Alzhei-
mer’s disease [40]. Other factors like patient age, gender,
co-morbidity, neuroleptic and antidepressant therapy,
and hospital admission in the previous year show no sig-
nificance after adjusting the multivariate logistic regres-
sion model.
We found that type of dementia, physician specialisa-
tion, co-morbidity, and neuroleptic therapy influenced
the prescription of any anti-dementia drug (i.e. cholines-
terase inhibitors, memantine and/or Ginkgo biloba).
While odds ratios for Alzheimer’s disease are presumably
higher than those for vascular dementia, it is in accor-
dance with the results of Formiga and Frisoni [36,40].
Moreover, there are several hints of different prescribing
patterns of neurologists and GPs [25,38]. Ruof et al.
found that neurologists prescribed cholinesterase inhibi-
tors to 44.6% of their Alzheimer patients, while GPs only
treated 9.0% of their patients with cholinesterase inhibi-
tors [41]. Thus, physician specialisation seems to be a
reasonable indicator for the prescription of any anti-
dementia drug. A prescription of neuroleptics could indi-
cate the presence of behavioural and psychological symp-
toms of dementia (BPSD) and these symptoms are more
common in the middle or severe stages of dementia.
Factors related to the prescription of Ginkgo biloba
The prescription of Ginkgo biloba was positively associated
with patient age, whereas the chance for the prescription
of Ginkgo biloba was smaller than 1 for women, patient
treatment by a neurologist, and patient diagnosed with
Alzheimer’s disease. Co-morbidities and antidepressant or
neuroleptic therapy did not reveal a significant impact,
which might be due to the small sample size. Our results
at first oppose the results of Nahin [42], who found that
use of herbal and dietary supplements in older people in
the United States was associated with female sex, a higher
income, and a higher MMSE score in multivariate analysis.
Although a subgroup analysis of factors related to the use
of Ginkgo biloba had shown only race (white vs. nonwhite)
as a significant factor, our results indicate that male
patients are more likely to be prescribed Ginkgo biloba.A t
first this seems to counter studies which show that females
are more likely to use CAM. However, it has to be noted
that in dementia patients, the spouse might be the com-
munication counterpart of the physician, which in the
majority of cases of male dementia patients can be
assumed to be the women. Thus, the predilection for
CAM might be transferred to the partner.
Most of the physicians who asked for Ginkgo biloba,
according to van den Bussche [25], assumed the potential
effectiveness of Ginkgo biloba: 85% of the neurologists and
59% of the GPs attribute a moderate to high effectiveness.
Thus it is not surprising that in our survey Ginkgo biloba
was mainly prescribed by a neurologist. This is under-
pinned by the survey of Hillmer [43] on prescribing prac-
tices of Canadian family physicians with regards to
Alzheimer’s disease. The survey found that perception and
self-reported knowledge are the most important factors
that significantly predict lower prescribing rates. In the
case of vascular dementia, there is no recommendation in
the guidelines. Compared to other forms of dementia and
taking the results of Hillmer into account, one therefore
would assume a higher application of ginkgo preparations,
which indeed was given in our data.
Neuroleptics
The prescribing frequency of antipsychotic drugs in geria-
tric patients is commonly overestimated particularly with
respect to the administration of benzodiazepines, which
are not recommended (DEGAM, DGN/DGPPN) [44] due
to higher mortality and a higher tendency to fall. Thus,
both conventional and atypical neuroleptics should only
be administered for a short period of time (DEGAM,
DGN/DGPPN) [18,19]. According to Meyer et al., 28.4%
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neuroleptics and 23.6% were prescribed anxiolytic or hyp-
notic medication, mostly butyrophenone [45]. These rates
do not differ from the 56.4% antipsychotic drugs being
prescribed to 888 residents in Munich nursing homes
[46]. Similar results were obtained from Mann et al. 2009
in Austria (antipsychotics 45.9%) [47], while the 31%
reported in Italy was slightly lower [36]. Our results of
only 14% thus are comparably low and might be explained
by the CAM-orientation of the physicians. However,
it is striking that benzodiazepines were mainly prescribed
by GPs, while there was no significant difference bet-
ween GPs and neurologists in the administration of
neuroleptics.
Concomitant use of anticholinergics and cholinesterase
inhibitors
In recent years an intensive and still ongoing debate on
the concomitant use of anticholinergics and cholinester-
ase inhibitors has emerged. It is assumed that anticholi-
nergics may attenuate the effects of cholinesterase
inhibitors. Other studies suggest that anticholinergics are
prescribed to palliate side effects of cholinesterase inhibi-
tors [48]. Data from registers from Australia and the
USA reveal a proportion of joint prescriptions between
20 and 47% [49-51]. Our sample is too low to draw con-
crete conclusions about the concomitant use of anticholi-
nergics and cholinesterase inhibitors; however, with only
one of 40 patients being prescribed this combined treat-
ment, one may assume that CAM-oriented physicians
might be more cautions in the concomitant use of antic-
holinergics and cholinesterase inhibitors.
Limitations
The present study has several important limitations
which should be taken into account when interpreting
the results. Firstly, additional data on the dementia diag-
noses are lacking, such as a functional evaluation with
the Barthel Index or an evaluation of the cognitive status
with the Mini Mental State Examination (MMSE). The
lack of objective tests for dementia massively increases
the possibility of misclassification bias with respect to
dementia type and severity. The proportion of Alzhei-
mer’s disease on all types of dementia normally should be
between 50% and 70%. This is not reflected in our study
which only found a proportion of about 10%. One expla-
nation might be that GPs mainly (57%) classified the
dementia as “unspecific”. Secondly, although physician
prescribing data were subjected to an internal review,
coding inaccuracies cannot be ruled out entirely. Thirdly,
data on subsequent medication use in patients who
switched physicians were unavailable. Finally our study
only presents data from a very small percentage of CAM
physicians in Germany. The participation of 22 out of a
possible 362 possible physicians does not support a
broad generalisability of our findings nor does it allow
carrying out detailed subgroup analyses. Thus, this analy-
sis as such, should be viewed as a first insight into this
field. In addition the present study also lacks a direct
comparison group. Further research on this subject
therefore would benefit from including a broader sample
of CAM physicians as well as a stratified comparison
group of conventional primary care physicians.
Conclusions
The present study provides a systematic overview of every-
day practice for treatment of dementia in primary care in
physicians with a CAM focus. Both physicians and
patients of our study are comparable to other studies,
except for their CAM specification. We also found low
prescribing rates of cholinesterase inhibitors and meman-
tine, while Ginkgo biloba in contrast to the German guide-
lines was prescribed quite often. Comparing CAM-GPs
and CAM neurologists, it is remarkable that GPs more
often prescribe the not recommended butyrophenone,
while neurologists mainly prescribe anti-dementia drugs.
The administration of neuroleptics in both groups of
physicians is comparable and considerably lower than in
other studies. Further analysis regarding co-medication,
co-morbidity, and the occurrence of critical combinations
are of high interest to health services research.
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